Abdullah TUNCEZ

Comparative effects of atorvastatin 80 mg versus rosuvastatin 40 mg on the neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and monocyte to HDL-cholesterol ratio in patients with acute myocardial infarction

Background: Previous studies have shown the association between the elevated levels of hematological markers like Neutrophilto Lymphocyte ratio (NLR), Platelet to lymphocyte ratio (PLR) and Monocyte to High density lipoprotein cholesterol (HDL-C) ratio(MHR) and increased risk of the existence of cardiovascular disease, increased risk of acute coronary syndromes and severity ofcardiovascular disease. One of the most commonly used drugs in atherosclerotic cardiovascular diseases are statins and we knowthat statins have beneficial effects in addition to LDL-lowering effects known as pleiotropic effects. However the effects of statinson the hematological markers are unclear. We performed this investigation to clarify and compare the effects of maximum-dose ofatorvastatin and rosuvastatin on hematological biomarkers in patients with acute myocardial infarction.Methods: Statin or other anti-lipid drugs naive patients with either ST-segment elevation myocardial infarction or Non-ST elevationmyocardial infarction were enrolled to our study. Biochemistry parameters, lipid parameters, blood-count parameters and NLR, PLRand MHR levels were measured at baseline and 30 days after discharge. Baseline characteristics and results of 2 groups after onemonthtreatment were compared.Results: Among the 128 statin-naive patients included, 65 patients received atorvastatin (80 mg/day) and 63 patients recievedrosuvastatin (40 mg/day). Baseline clinical characteristics of groups were similar. Atorvastatin 80 mg significantly decreased thelevels of NLR (p=0.001) and MHR (p=0.024) at the end of one-month therapy. Rosuvastatin 40 mg also significantly decreased thelevels of NLR (p=0.001) and MHR (p=0.006) at the end of one-month therapy. Both statins were ineffective on the levels of PLR.Percent and absolute changes of NLR, MHR and PLR were similar and there were no statistically significant differences between bothgroups. The percent and absolute changes of lipid parameters were also similar among both treatment arms.Conclusion: Our results showed that atorvastatin 80 mg and rosuvastatin 40 mg decreased the NLR and MHR levels significantly atthe end of one-month therapy. However, both statins have no effects on PLR levels.

PDF

___

1. The top 10 causes of death. http://www.who.int/ mediacentre/factsheets/fs310/en/. accessed date 07.03.2017
2. Furman MI, Gore JM, Anderson FA, et al. Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2004;147:42- 8.
3. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005;45:1638-43.
4. Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol 2000;86:449-51.
5. Cho KH, Jeong MH, Ahmed K, et al. Value of Early Risk Stratification Using Hemoglobin Level and Neutrophil-to- Lymphocyte Ratio in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. American Journal of Cardiology 2011;107:849- 56.
6. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality After Non-ST-Elevation Myocardial Infarction. Am J Cardiol. 2010;106:470-6.
7. Nunez J, Nunez E, Bodi V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008;101:747-52.
8. Gul M, Uyarel H, Ergelen M, et al. Predictive Value of Neutrophil to Lymphocyte Ratio in Clinical Outcomes of Non-ST Elevation Myocardial Infarction and Unstable Angina Pectoris A 3-Year Follow-Up. Clin Appl Thromb- Hem 2014;20:378-84.
9. Tanık VO, Çınar T, Velibey Y, et al. Neutrophil-to-lymphocyte ratio predicts contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. J Tehran Univ Heart Cent 2019;14:59-66.
10. Thaulow E, Erikssen J, Sandvik L, et al. Blood-platelet count and function are related to total and cardiovascular death in apparently healthy-men. Circulation 1991;84:613-7.
11. Iijima R, Ndrepepa G, Mehilli J, et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions - Pooled analysis of four ISAR trials. Thromb Haemostasis 2007;98:852-7.
12. Bian C, Wu Y, Shi Y, et al. Predictive value of the relative lymphocyte count in coronary heart disease. Heart Vessels 2010;25:469-73.
13. Smith RA, Bosonnet L, Raraty M, et al. Preoperative plateletlymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-72.
14. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-641.
15. Cetin EHO, Cetin MS, Aras D, et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and longterm major adverse cardiovascular events in ST-segment elevation myocardial infarction. Angiology 2016;67:336-45.
16. Azab B, Shah N, Akerman M, et al. Value of platelet/ lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolys 2012;34:326-34.
17. Kurtul A, Murat SN, Yarlioglues M, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol 2014;114:972-8.
18. Olivares R, Ducimetiere P, Claude JR. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol 1993;137:49-53.
19. Ansell BJ, Navab M, Hama S, et al. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6.
20. Cicek G, Kundi H, Bozbay M, et al. The relationship between admission monocyte HDL-C ratio with short-term and long-term mortality among STEMI patients treated with successful primary PCI. Coronary Artery Dis 2016;27:176- 84.
21. Kundi H, Kiziltunc E, Cetin M, et al. Association of monocyte/ HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz 2016;41:523-9.
22. Tosu A, Çinar, T , Güler, A , et al. The usefulness of monocyte to high density lipoprotein cholesterol ratio in prediction for coronary artery ectasia. Turk J Clin Laborat 2019;10:68-73.
23. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344.
24. Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. Circulation. 2012;126:2020-
25. Amsterdam. 2014 ACC/AHA Guideline for the management of patients with non-st-elevation acute coronary syndromes: executive summary: a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;130:431-2.
26. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
27. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Identification of Macrophages and smooth-muscle cells in human atherosclerosis using monoclonal-antibodies. J Pathol 1985;146:197-204.
28. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
29. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006;109:7-15.
30. Pitt B, Loscalzo J, Monyak J, et al. Comparison of Lipid- Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol 2012;109:1239-46.
31. Aydin MU, Aygul N, Altunkeser BB, et al. Comparative effects of high-dose atorvastatin versus moderatedose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis 2015;239:439-43.
32. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New Engl J Med 2008;359:2195-207.
33. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-6.
34. Gungoren F, Besli F, Caliskan S, et al. Statin Therapy May not Effect NLR and MPV Levels in Patients With Hypercholesterolemia: A Retrospective Study. Angiology 2016;67:536-40.
35. Akin F, Ayca B, Kose N, et al. Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Angiology 2013;64:621-625
36. Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol-Canc 2003;26:135-40.
37. Yildiz A, Yuksel M, Oylumlu M, et al. The Utility of the Platelet-Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost 2015;21:223-8.
38. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
39. Akboga MK, Canpolat U, Yuksel M, et al. Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: A single center large-scale study. Platelets 2016;27:178-83.
40. Kei A, Elisaf M. Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. Arch Med Sci 2014;10:439-44.
41. Karatas MB, Canga Y, Ozcan KS, et al. Monocyte to highdensity lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med 2016;34:240-4.
42. Canpolat U, Aytemir K, Yorgun H, et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoonbased catheter ablation. Europace 2015;17:1807-15.
43. 43. Tani S, Nagao K, Anazawa T, et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 2009;104:464-9.
44. Fildes JE, Shaw SM, Mitsidou A, et al. HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transpl Immunol 2008;19:152-7.
45. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556- 65.